Provention Bio (PRVB) Scheduled to Post Earnings on Thursday

Provention Bio (NASDAQ:PRVB) will be releasing its earnings data before the market opens on Thursday, February 25th. Analysts expect Provention Bio to post earnings of ($0.50) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Shares of NASDAQ:PRVB opened at $15.49 on Tuesday. The company’s fifty day moving average price is $15.39 and its 200 day moving average price is $14.55. Provention Bio has a 12 month low of $4.72 and a 12 month high of $20.05. The firm has a market capitalization of $875.00 million, a P/E ratio of -10.40 and a beta of 3.34.

Several brokerages recently commented on PRVB. Zacks Investment Research upgraded shares of Provention Bio from a “sell” rating to a “hold” rating in a research note on Friday. Chardan Capital lifted their price target on shares of Provention Bio from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, January 4th. Finally, HC Wainwright lifted their price target on shares of Provention Bio from $26.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $28.80.

About Provention Bio

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.

See Also: What is the FTSE 100 index?

Earnings History for Provention Bio (NASDAQ:PRVB)

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.